12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cubist, Heptares deal

Heptares received an undisclosed milestone payment from Cubist under a January deal to discover and develop compounds against two undisclosed GPCR targets...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >